VIP and CIRS: How Vasoactive Intestinal Peptide Treats Chronic Inflammation

What Is CIRS?

Chronic Inflammatory Response Syndrome (CIRS) is a multi-system, multi-symptom illness caused by exposure to biotoxins — most commonly from water-damaged buildings (mould), but also from tick-borne infections (Lyme disease), cyanobacteria (blue-green algae), and certain dinoflagellates.

CIRS was first characterised by Dr. Ritchie Shoemaker, a family physician in Maryland who noticed that clusters of patients living near water-damaged buildings developed a consistent pattern of symptoms that defied conventional diagnosis.

The HLA Genetic Susceptibility

What makes CIRS unique is that it does not affect everyone equally. Approximately 24–25% of the population carries HLA-DR gene variants that prevent their immune system from properly recognising and clearing biotoxins.

In individuals with normal HLA genes:

1. Biotoxin enters the body
2. Antigen-presenting cells display it to T-cells
3. Antibodies are generated
4. The biotoxin is tagged for clearance
5. The immune response resolves

In HLA-susceptible individuals:

1. Biotoxin enters the body
2. Antigen-presenting cells cannot properly present it to T-cells
3. No effective antibody response is generated
4. The biotoxin circulates indefinitely, triggering chronic innate immune activation
5. The inflammatory response never resolves

This chronic activation produces a cascade of measurable inflammatory markers: elevated TGF-beta-1, C4a, MMP-9, VEGF, MSH deficiency, and ADH dysregulation — creating symptoms that affect virtually every organ system.

CIRS Symptoms

The symptom profile is broad and often leads to misdiagnosis as fibromyalgia, chronic fatigue syndrome, depression, or anxiety:

• Fatigue and weakness
• Cognitive impairment ("brain fog" — difficulty with word finding, memory, concentration)
• Joint pain and morning stiffness
• Headaches
• Shortness of breath, air hunger
• Sinus congestion
• Light sensitivity
• Temperature dysregulation
• Abdominal pain, diarrhea
• Numbness and tingling
• Mood changes (anxiety, depression, irritability)
• Insomnia and non-restorative sleep

The Shoemaker Protocol

Dr. Shoemaker developed a sequential treatment protocol based on decades of clinical experience and published research. The protocol follows a specific order — each step must be completed before progressing to the next:

1. Remove from exposure — Remediate or leave the water-damaged building
2. Cholestyramine or Welchol — Bile acid sequestrants that bind biotoxins in the GI tract for elimination
3. Correct MARCoNS — Treat Multiple Antibiotic Resistant Coagulase Negative Staphylococci (deep nasal biofilm)
4. Correct anti-gliadin antibodies — Address gluten sensitivity if present
5. Correct androgens — Address DHEA/testosterone abnormalities
6. Correct ADH/osmolality — Address antidiuretic hormone dysregulation
7. Correct MMP-9 — Address matrix metalloproteinase elevation
8. Correct VEGF — Address vascular endothelial growth factor abnormalities
9. Correct C3a — Address complement activation
10. Correct C4a — Address complement activation
11. Correct TGF-beta-1 — Address fibrosis-promoting cytokine
12. VIP nasal spray — The final step: restore regulatory neuropeptide function

VIP is the capstone of the protocol — it is only used after all upstream inflammatory triggers have been addressed.

VIP Biology

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide first isolated from the porcine small intestine in 1970 by Sami Said and Viktor Mutt. Despite its name, VIP is not limited to the gut — it is widely distributed throughout the body:

• Gastrointestinal tract: Relaxes smooth muscle, stimulates water and electrolyte secretion, regulates gut motility
• Brain: Functions as a neurotransmitter and neuromodulator; high concentrations in the hypothalamus, hippocampus, and cerebral cortex
• Immune system: Expressed by immune cells and acts on VPAC1 and VPAC2 receptors on T-cells, macrophages, and dendritic cells
• Lungs: Bronchodilation and pulmonary vasodilation
• Heart: Positive inotropic and chronotropic effects

VIP binds to three receptors: VPAC1, VPAC2, and PAC1 — all G-protein coupled receptors that activate adenylyl cyclase and increase intracellular cAMP.

VIP's Anti-Inflammatory Mechanism

VIP is one of the most potent endogenous anti-inflammatory molecules known. Its mechanism includes:

Cytokine Suppression

• Suppresses TNF-alpha production by macrophages (one of the primary inflammatory drivers in CIRS)
• Reduces IL-6 (a key acute-phase inflammatory cytokine)
• Inhibits IL-12 (which drives Th1 inflammatory responses)
• Reduces IL-17 (Th17-mediated inflammation)

Regulatory T-Cell Promotion

• VIP promotes the differentiation and expansion of regulatory T-cells (Tregs)
• Tregs suppress excessive immune activation and restore immune homeostasis
• This is the same mechanism that makes VIP therapeutic rather than immunosuppressive — it restores balance, not suppression

Dendritic Cell Modulation

• VIP shifts dendritic cells from a pro-inflammatory to a tolerogenic phenotype
• Tolerogenic dendritic cells promote immune tolerance rather than immune activation
• This reduces the chronic innate immune activation that drives CIRS symptoms

VIP's Role in the Shoemaker Protocol

In the CIRS treatment protocol, VIP addresses the final piece: restoring regulatory neuropeptide function after the upstream inflammatory triggers have been removed.

Shoemaker's published data shows that VIP nasal spray (50 mcg four times daily) in CIRS patients who have completed prior protocol steps produces:

• Normalisation of TGF-beta-1 (often from >5,000 pg/mL to <2,380 pg/mL)
• Normalisation of C4a complement markers
• Normalisation of VEGF
• Restoration of MSH (alpha-melanocyte stimulating hormone) levels
• Improvement in pulmonary function (VO2 max, pulmonary artery pressures)
• Dramatic improvement in fatigue, cognition, and quality of life

Importantly, VIP should not be used before completing earlier protocol steps. If biotoxin exposure is ongoing or if MARCoNS nasal biofilm is present, VIP can theoretically promote biofilm growth. This is why the sequential protocol matters.

Beyond CIRS: Other Applications

Mast Cell Activation Syndrome (MCAS)

MCAS — a condition of excessive mast cell degranulation causing histamine-mediated symptoms (flushing, hives, GI symptoms, anaphylaxis-like reactions) — often overlaps with CIRS. VIP stabilises mast cells and reduces histamine release, making it a valuable therapeutic tool for MCAS patients.

Post-Viral Inflammatory Conditions

The COVID-19 pandemic highlighted a phenomenon long recognised in CIRS medicine: some individuals develop persistent, multi-system inflammatory responses after viral infection. These "long-haul" conditions share features with CIRS:

• Chronic fatigue
• Cognitive impairment
• Dysautonomia (POTS, heart rate variability changes)
• Persistent inflammatory markers

VIP's broad anti-inflammatory profile — suppressing TNF-alpha, IL-6, and promoting Tregs — makes it a rational therapeutic approach for post-viral inflammation.

Gut Barrier Integrity

VIP plays a direct role in maintaining intestinal barrier function:

• Promotes tight junction protein expression (claudins, occludin, ZO-1)
• Reduces intestinal permeability ("leaky gut")
• Modulates the gut-associated lymphoid tissue (GALT)
• Supports the gut-brain axis via vagal nerve signalling

In patients with CIRS, gut barrier dysfunction is common — VIP helps restore it as part of the systemic recovery.

Practical Dosing

Intranasal Protocol (Standard — Shoemaker Protocol)

• Dose: 50 mcg per spray, 4 times daily
• Duration: 30 days initially; many patients continue for 6–12 months
• Prerequisites: Complete Shoemaker protocol steps 1–11; confirm negative MARCoNS culture
• Storage: Refrigerate; compounded by specialty pharmacies

Subcutaneous Protocol (Alternative)

• Dose: 50–100 mcg subcutaneous, 1–2 times daily
• Duration: 4–8 weeks
• Notes: Some practitioners prefer subcutaneous for more consistent systemic delivery

Monitoring

• TGF-beta-1, C4a, C3a: Repeat at 30 days to assess inflammatory marker response
• VEGF, MSH, MMP-9: Repeat at 30–60 days
• Pulmonary function: VO2 max testing if available
• Symptom tracking: Validated CIRS symptom questionnaires

The Bottom Line

CIRS is a real, measurable, treatable condition that affects roughly one in four people who are exposed to water-damaged buildings. VIP — a naturally occurring neuropeptide with powerful anti-inflammatory, immunoregulatory, and neuroprotective properties — is the final and often most transformative step in the Shoemaker protocol. Its applications extend beyond CIRS to mast cell activation, post-viral inflammation, and gut barrier repair. For anyone dealing with chronic, unexplained multi-system inflammation, VIP deserves serious clinical consideration.

Mito Labs provides pharmaceutical-grade VIP for intranasal and subcutaneous use, with full analytical testing and clinical guidance. Our team can help integrate VIP into a comprehensive inflammatory recovery protocol.